Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jiangsu Atom Closes $45 Million Round for Global Phase III Gout Trial

publication date: Jan 5, 2022

Jiangsu Atom Bioscience closed a $45 million Series C financing to support a global Phase III clinical trial of ABP-671, its lead small molecule drug for hyperuricemia and gout, along with preclinical/clinical development of other pipeline products. The company develops novel small molecule candidates for inflammatory and metabolic diseases such as chronic gout and non-alcoholic steatohepatitis. To date, Atom has raised a total of $87 million. The Series C was led by Xicheng Jinrui Equity Investment Fund and ShenZen GTJA Investment Group. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here